4.4 Article

Polysubstance use in inflammatory bowel disease

Journal

JOURNAL OF DIGESTIVE DISEASES
Volume 22, Issue 12, Pages 706-713

Publisher

WILEY
DOI: 10.1111/1751-2980.13064

Keywords

antidepressant and; or anxiolytic use; extraintestinal manifestation; healthcare resource utilization; inflammatory bowel disease; polysubstance use

Funding

  1. Margot E. Walrath Career Development Professorship in Gastroenterology
  2. National Institute of Diabetes and Digestive and Kidney Diseases [R01DK122364]
  3. Peter and Marsha Carlino Early Career Professorship in Inflammatory Bowel Disease

Ask authors/readers for more resources

This study aimed to evaluate the incidence, predisposing factors, and impacts of polysubstance use (PSU) in patients with inflammatory bowel disease (IBD). The results showed that PSU was associated with an increased rate of IBD-associated imaging studies.
Objectives We aimed to evaluate the incidence, predisposing factors and impacts of polysubstance use (PSU) (ie, the concurrent use or abuse of two or more drugs or substances) in inflammatory bowel disease (IBD). Methods Data of patients enrolled between 1 January 2015 and 31 August 2019 from a single tertiary care referral center were retrospectively collected. Patients' baseline and clinical characteristics and their antidepressant and/or anxiolytic medications were abstracted. Associations between PSU and patients' characteristics were analyzed. Multivariate logistic regression models were fit, incorporating significant clinical factors. Results Altogether 315 patients with IBD (166 women, 149 men; 214 with Crohn's disease and 101 ulcerative colitis) were enrolled. Of them, 66 (21.0%) exhibited PSU (CD 21.5%, UC 19.8%); 37.5% had moderate to severe disease activity, 34.3% with extraintestinal manifestations (EIM), 41.6% with an anxious or depressed state and 69.8% had used healthcare resources in the prior 12 months. Moreover, 71.2% used two substances, while 27.3% used three substances. In the total cohort, EIM (odds ratio [OR] 1.97, 95% confidence interval [CI] 1.14-3.34, P = 0.019) and antidepressant or anxiolytic use (OR 2.51, 95% CI 1.45-4.39, P < 0.001) were positively associated with PSU on multivariate analysis. PSU was associated with increased rate of IBD-associated imaging (57.6% vs 47.0%, P < 0.05). Conclusions PSU is common in IBD. EIM, antidepressant and/or anxiolytic use and imaging studies were independently associated with PSU. This study reinforces the importance of screening patients with IBD for substance use, particularly those with EIM and using antidepressants and/or anxiolytics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available